Table 1 In silico signaling identification using gene set variation analysis (GSVA)

From: Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study

Patient ID	GSVA 1st			GSVA 2nd			GSVA 3rd
Patient ID	Target	ES	Potential therapy	Target	ES	Potential therapy	Target	ES	Potential therapy
MCL1	CAR T	0.407	CAR T	PI3Kα	0.345	Copanlisib	PI3K-Akt	0.342	Fimepinostat
MCL2	MDM2	0.757	RG7112	HDAC	0.649	Vorinostat	PI3K-Akt	0.429	Fimepinostat
MCL3	Proteasome	0.475	Carfilzomib	BTK	0.424	Reversible Pirtobrutinib	CDK	0.365	Abemaciclib
MCL4	HDAC	0.389	Vorinostat	PLK1	0.233	Volasertib	AKT/ERK	0.2	Fimepinostat/ONC-201
MCL5	OXPHOS	0.616	IACS-010759	MALT1	0.609	MI-2	BCL-2	0.468	Venetoclax
MCL6	MALT1	0.566	MI-2	BCL-2	0.522	Venetoclax	HDAC	0.459	Vorinostat
MCL7	PARP	0.669	Olaparib	BCL-2	0.542	Venetoclax	MALT1	0.406	MI-2
MCL8	HDAC	0.515	Vorinostat	PI3K-Akt	0.378	Fimepinostat	PI3Kα	0.292	Copanlisib
MCL9	TrxR	0.512	Auranofin	CAR T	0.232	CAR T	PI3Kα	0.185	Copanlisib
MCL10	PI3K-Akt	0.35	Fimepinostat	CAR T	0.3	CAR T	PI3K/HDAC	0.274	Copanlisib/Vorinostat
MCL11	Proteasome	0.86	Carfilzomib	TrxR	0.493	Auranofin	MALT1	0.446	MI-2
MCL12	Proteasome	0.881	Carfilzomib	MDM2	0.803	RG7112	OXPHOS	0.723	IACS-010759
MCL13	MDM2	0.782	RG7112	MALT1	0.234	MI-2	HDAC	0.223	Vorinostat
MCL14	PI3K-Akt	0.419	Fimepinostat	AKT/ERK	0.418	Fimepinostat/ONC-201	HDAC	0.371	Vorinostat
MCL15	PLK1	0.422	Volasertib	CDK	0.212	Abemaciclib	PARP	0.026	Olaparib
MCL16	Proteasome	0.677	Carfilzomib	OXPHOS	0.576	IACS-010759	PARP	0.553	Olaparib
MCL17	PLK1	0.592	Volasertib	CDK	0.533	Abemaciclib	CAR T	0.497	CAR T
MCL18	PLK1	0.569	Volasertib	CDK	0.554	Abemaciclib	Proteasome	0.379	Carfilzomib
MCL19	Proteasome	0.886	Carfilzomib	PLK1	0.683	Volasertib	CDK	0.65	Abemaciclib
MCL20	Proteasome	0.547	Carfilzomib	CDK	0.502	Abemaciclib	TrxR	0.463	Auranofin

Ranked enrichment scores (ES) were determined by the GSVA algorithm and were used to choose potentially beneficial matched targeted therapeutics.

Back to article page

Quick links

Search

Quick links